Summary of findings 6. RISPERIDONE DEPOT compared with ORAL OLANZAPINE for schizophrenia.
| RISPERIDONE DEPOT compared with ORAL OLANZAPINE for schizophrenia | ||||||
| Patient or population: patients with schizophrenia Settings: Intervention: RISPERIDONE DEPOT Comparison: ORAL OLANZAPINE | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| ORAL OLANZAPINE | RISPERIDONE DEPOT | |||||
| Global state: Relapse ‐ long term | See comment | See comment | Not estimable | 0 (0) | See comment | Outcomes relating to relapse were not reported for this comparison. |
| Mental state: Average change scores ‐ long term PANSS total score (30‐210), high scores are worse. | The mean mental state: average change scores ‐ long term in the intervention groups was 0.1 higher (3.96 lower to 4.16 higher) | 361 (1 study) | ⊕⊕⊝⊝ low1,2,3 | |||
| Leaving the study early: Any reason ‐ long term | Study population | RR 1.32 (1.1 to 1.58) | 618 (1 study) | ⊕⊕⊝⊝ low1,2,3 | ||
| 377 per 10004 | 497 per 1000 (414 to 595) | |||||
| Moderate | ||||||
| 377 per 10004 | 498 per 1000 (415 to 596) | |||||
| Adverse events: General ‐ serious | Moderate | RR 1.1 (0.8 to 1.51) | 547 (1 study) | ⊕⊕⊝⊝ low1,2,3 | ||
| 210 per 10004 | 231 per 1000 (168 to 317) | |||||
| Adverse events: Movement disorder ‐ any extra pyramidal symptoms | Moderate | RR 1.67 (1.19 to 2.36) | 547 (1 study) | ⊕⊕⊝⊝ low1,2,3 | ||
| 150 per 10004 | 250 per 1000 (179 to 354) | |||||
| Adverse events: Specific ‐ weight increase | Moderate | RR 0.56 (0.42 to 0.75) | 547 (1 study) | ⊕⊕⊝⊝ low1,2,3 | ||
| 360 per 10004 | 202 per 1000 (151 to 270) | |||||
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; RR: Risk ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 Risk of bias: 'very serious' ‐ serious risk of bias due to study attrition in excess of 50%. 2 Risk of bias: 'serious' ‐ serious risk of bias as this study was supported by the manufacturers of risperidone depot, and some of the authors are employed by the same. 3 Risk of bias: 'serious' ‐ serious risk of bias due to the open‐label nature of the study. 4 Assumed risk: mean baseline risk from one included study.